11 Best Low Cost Stocks to Buy According to Analysts

Page 5 of 10

6. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Forward P/E Ratio: 14.12

Number of Hedge Fund Holders: 73

Analyst Upside Potential: 36.91%

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Best Low Cost Stocks to Buy According to Analysts. On September 8, Evan Seigerman from BMO Capital maintained a Buy rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) with a price target of $640.

The analyst noted that his rating is based on the strong results from Phase 3 trials for the company’s cat and birch allergy antibody cocktails. The results showed significant symptom reduction with key improvements seen in ocular itch, redness, and skin reaction, especially for cat allergy patients sensitized to FelD1.

Seigerman notes the clinical data address a large unmet medical need. However, he also points out uncertainty about commercial uptake due to generic antihistamines dominating allergy treatment. Despite this, he remains positive on Regeneron Pharmaceuticals, Inc.’s (NASDAQ:REGN overall outlook.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a biotechnology company that develops, manufactures, and sells medicines for serious diseases.

Page 5 of 10